Ionis Pharmaceuticals is trading at $43.88 (-4.08%) on September 23, 2026, as broader risk-off trading and lingering Tryngolza launch concerns appear to weigh on shares despite positive interim sefaxersen results.
- Roche’s Phase 3 study met its primary endpoint, with statistically significant proteinuria reduction and no new safety signals.
- Higher oil prices and Treasury yields near 4.99% add to market pressure; JPMorgan cut its target to $70 from $76.